Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead Sciences (GILD) shares have outperformed the S&P 500 and its industry over the past month, returning +11.1%. Current fiscal year earnings are projected to increase 71.2%, while revenue is expected to decline slightly by 0.4%; next fiscal year revenue is expected to increase 4.4%. Despite recent outperformance, Gilead carries a Zacks Rank #3, suggesting near-term performance in line with the broader market, and is currently trading at a discount to its peers.

Analysis

Gilead Sciences (GILD) has exhibited notable recent stock strength, with an 11.1% return over the past month, surpassing both the S&P 500's 6.6% gain and its Zacks Medical - Biomedical and Genetics industry's 10.9% increase. Current quarter earnings per share (EPS) are anticipated at $1.99, a marginal 1.0% year-over-year decrease, with the Zacks Consensus Estimate for this period remaining unchanged over the last 30 days. A significant 71.2% year-over-year EPS growth to $7.91 is projected for the current fiscal year, though this estimate has also been stable recently. For the next fiscal year, analysts project EPS of $8.48, a 7.1% increase from the current year's expectation, and this estimate has seen a positive 1.1% revision over the past month. Revenue projections indicate a 0.6% year-over-year increase to $7 billion for the current quarter, a slight 0.4% decline to $28.64 billion for the current fiscal year, followed by an anticipated 4.4% growth to $29.89 billion for the next fiscal year. In its last reported quarter, Gilead's revenue of $6.67 billion (a 0.3% year-over-year decrease) and EPS of $1.81 missed consensus estimates by -2.46% and -0.55% respectively; however, the company has surpassed consensus EPS estimates three times and revenue estimates three times over the last four quarters. The stock currently holds a Zacks Rank #3 (Hold), suggesting its near-term performance may align with the broader market, and it possesses a Zacks Value Style Score of B, indicating it is trading at a discount relative to its peers.

Key Decisions for Investors

• Investors should consider that Gilead's recent 11.1% stock price appreciation over the past month may temper immediate further upside, aligning with its Zacks Rank #3 (Hold) which suggests near-term market-perform expectations.
• The substantial projected current fiscal year EPS growth of +71.2% and next fiscal year EPS growth of +7.1% are key positives, but the recent stability in consensus estimates for the current periods warrants monitoring for upward revisions that could provide further catalysts.
• It is prudent to weigh the attractive valuation, evidenced by a Zacks Value Style Score of B indicating a discount to peers, against the mixed fundamental picture that includes modest near-term revenue forecasts (current FY -0.4%, next FY +4.4%) and a recent miss on quarterly revenue and EPS estimates.